Valuation : Control Bionics Limited

Market Cap 30.49M 21.93M 18.82M 17.62M 16.14M 30.4M 2.09B 209M 81.58M 1.06B 82.33M 80.55M 3.49B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.76M 18.68M 17.49M 16.01M 30.16M 2.08B 207M 80.94M 1.05B 81.69M 79.93M 3.47B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
73.48%
Yield 2024 *
-
Yield 2025 -
1 day-1.64%
Current month-6.25%
1 month-11.76%
6 months+7.14%
Current year-1.64%
1 week 0.06
Extreme 0.057
0.06
1 month 0.06
Extreme 0.056
0.07
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.73
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Director/Board Member - 01/04/2023
Change 5-day change 1-year change 3-year change Capi.($)
-1.64%0.00%+50.00%-22.08% 19.47M
+2.45%+0.60%+29.44%-29.00% 17.61B
+15.78%+0.07%-30.47%+110.64% 1.7B
+2.05%+3.03%-44.90%-80.19% 1.02B
+0.84%-2.37%-25.82%+21.93% 951M
+0.08%+0.03%+61.53%-5.54% 779M
+2.67%+1.05%-38.28%-44.75% 690M
+3.43%-8.53%-44.27%-48.79% 550M
+2.06%+4.35%-38.26%-36.14% 452M
+5.30%+5.85%+73.89%+50.69% 429M
Average +3.37%+1.86%-0.71%-8.32% 2.42B
Weighted average by Cap. +3.12%+3.75%+16.89%-18.24%

Financials

2024 2025
Net sales 5.35M 3.85M 3.3M 3.09M 2.83M 5.34M 368M 36.63M 14.32M 185M 14.45M 14.14M 613M 6.14M 4.42M 3.79M 3.55M 3.25M 6.13M 422M 42.06M 16.44M 213M 16.6M 16.24M 704M
Net income -5.91M -4.25M -3.65M -3.42M -3.13M -5.9M -406M -40.48M -15.82M -205M -15.97M -15.63M -678M -6.11M -4.39M -3.77M -3.53M -3.23M -6.09M -420M -41.82M -16.35M -212M -16.5M -16.14M -700M
Net Debt -96.95K -69.74K -59.86K -56.04K -51.32K -96.67K -6.66M -664K -259K -3.36M -262K -256K -11.11M -237K -171K -146K -137K -126K -237K -16.3M -1.62M -635K -8.21M -641K -627K -27.19M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
27/08/26 A$0.0600 -1.64% 4,922,270
26/08/26 A$0.0610 +3.39% 145,482
25/08/26 A$0.0590 +1.72% 491,456
24/08/26 A$0.0580 -3.33% 296,570
21/08/26 A$0.0600 0.00% 704,803

Annual profits - Rate of surprise